Literature DB >> 2898985

The role of alpha-adrenoceptor blockade in the antihypertensive effects of fenoldopam in humans.

M B Murphy1, R R Weber, K Nelson, L I Goldberg.   

Abstract

Fenoldopam, a dopamine-1 receptor agonist, has been reported to exhibit alpha-adrenoceptor-blocking actions in intact and isolated animal preparations. To determine whether alpha-adrenoceptor blockade contributes to its antihypertensive properties in humans, the effects of fenoldopam on the pressor responses to norepinephrine and angiotensin II were compared in eight normal volunteers. Fenoldopam (0.5 micrograms/kg/min) shifted the dose-response curves for both agonists to the right (p less than 0.05). Dose ratios for an increase in mean blood pressure of 10 mm Hg were 3.3 +/- 0.9 for norepinephrine and 3.2 +/- 0.6 for angiotensin II (p not significant). Consequently, fenoldopam is not a selective alpha-adrenoceptor antagonist at therapeutic concentrations in humans.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2898985     DOI: 10.1038/clpt.1988.111

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

Review 1.  New dopamine receptor agonists in heart failure and hypertension. Implications for future therapy.

Authors:  P T Horn; M B Murphy
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

2.  A single dose study of the effects of fenoldopam and enalapril in mild hypertension.

Authors:  T M MacDonald; R F Jeffrey; S Freestone; M R Lee
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies.

Authors:  R N Brogden; A Markham
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

4.  Fenoldopam Sensitizes Primary Cilia-Mediated Mechanosensing to Promote Osteogenic Intercellular Signaling and Whole Bone Adaptation.

Authors:  Milos Spasic; Michael P Duffy; Christopher R Jacobs
Journal:  J Bone Miner Res       Date:  2022-03-23       Impact factor: 6.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.